{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:11:42Z","timestamp":1771067502759,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jaad.2017.03.023","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T04:39:56Z","timestamp":1499920796000},"page":"302-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Herpes zoster in psoriasis patients treated with tofacitinib"],"prefix":"10.1016","volume":"77","author":[{"given":"Kevin L.","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"Rottinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotus","family":"Mallbris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Rr-5","key":"10.1016\/j.jaad.2017.03.023_bib1","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.jaad.2017.03.023_bib2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00002508-200211000-00002","article-title":"Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy","volume":"18","author":"Schmader","year":"2002","journal-title":"Clin J Pain"},{"issue":"6","key":"10.1016\/j.jaad.2017.03.023_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin J Pain"},{"issue":"11","key":"10.1016\/j.jaad.2017.03.023_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.jaad.2017.03.023_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.023_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jama.2011.67","article-title":"Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans","volume":"305","author":"Schmajuk","year":"2011","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2017.03.023_bib7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/annrheumdis-2014-eular.5983","article-title":"FRI0193 herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination","volume":"73","author":"Curtis","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2017.03.023_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.jaad.2017.03.023_bib9","unstructured":"US Food and Drug Administration. FDA approves Xeljanz for rheumatoid arthritis. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm327152.htm. Last update 2012. Accessed 7 October 2015."},{"key":"10.1016\/j.jaad.2017.03.023_bib10","unstructured":"US Food and Drug Administration. What is a serious adverse event? Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/HowToReport\/ucm053087.htm. Last update 2014. Accessed 3 December 2015."},{"issue":"10","key":"10.1016\/j.jaad.2017.03.023_bib11","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.03.023_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2188\/jea.JE20140210","article-title":"Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study","volume":"25","author":"Takao","year":"2015","journal-title":"J Epidemiol"},{"issue":"22","key":"10.1016\/j.jaad.2017.03.023_bib13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2017.03.023_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jmv.21687","article-title":"Detection of varicella-zoster virus DNA in 414 human trigeminal ganglia from cadavers by the polymerase chain reaction: a comparison of the detection rate of varicella-zoster virus and herpes simplex virus type 1","volume":"82","author":"Inoue","year":"2010","journal-title":"J Med Virol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2017.03.023_bib15","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/522162","article-title":"The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review","volume":"197","author":"Reynolds","year":"2008","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jaad.2017.03.023_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1017\/S0950268812002671","article-title":"Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster","volume":"141","author":"Okuno","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.jaad.2017.03.023_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcv.2012.06.008","article-title":"A community-based survey of varicella-zoster virus-specific immune responses in the elderly","volume":"55","author":"Tang","year":"2012","journal-title":"J Clin Virol"},{"issue":"9","key":"10.1016\/j.jaad.2017.03.023_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2017.03.023_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent populiation in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.023_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2017.03.023_bib21","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2017.03.023_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/1079990041689665","article-title":"Induction and regulation of IFNs during viral infections","volume":"24","author":"Malmgaard","year":"2004","journal-title":"J Interferon Cytokine Res"},{"issue":"9","key":"10.1016\/j.jaad.2017.03.023_bib23","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jaad.2017.03.023_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/iai.32.1.24-27.1981","article-title":"Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged","volume":"32","author":"Berger","year":"1981","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.jaad.2017.03.023_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/592219","article-title":"Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay","volume":"198","author":"Sadaoka","year":"2008","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.jaad.2017.03.023_bib26","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1002\/cncr.28325","article-title":"Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials","volume":"119","author":"Nooka","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2017.03.023_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jaad.2017.03.023_bib28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.023_bib29","first-page":"95","article-title":"Noninfluenza vaccination coverage among adults-United States, 2012","volume":"63","author":"Williams","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.jaad.2017.03.023_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7326\/0003-4819-152-9-201005040-00005","article-title":"Barriers to the use of herpes zoster vaccine","volume":"152","author":"Hurley","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2017.03.023_bib31","unstructured":"Schiller J, Euler G. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Available at: http:\/\/www.cdc.gov\/nchs\/data\/hestat\/vaccine_coverage\/vaccine_coverage.pdf. Last update 2009. Accessed 28 July 2010."},{"issue":"6","key":"10.1016\/j.jaad.2017.03.023_bib32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.vaccine.2008.11.077","article-title":"Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors","volume":"27","author":"Lu","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jaad.2017.03.023_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2011.11.931","article-title":"Refusal of shingles vaccine: implications for public health","volume":"66","author":"Funovits","year":"2012","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217303821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217303821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:44:30Z","timestamp":1759272270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217303821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0190962217303821"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.03.023","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster in psoriasis patients treated with tofacitinib","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}